Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.

NCT07619508 · Completed

Last updated 2026-07-12

This clinical trial compares the effects of tirzepatide and semaglutide on heart-related outcomes in adults with obesity or overweight who are at risk for cardiovascular disease but do not have diabetes.

Status Completed The study has finished.

Type Observational

Participants 100,000 people

Who can join Ages 18+ · all sexes

Timeline Started 2026-02 · est. completion 2026-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT07619508 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

Tirzepatide Drug

Initiation of tirzepatide described in electronic health records is used as the exposure.
Semaglutide Drug

Initiation of injectable semaglutide described in electronic health records is used as the reference.

Main thing measured	Composite of all-cause mortality, myocardial infarction, or stroke.
Sponsor	Brigham and Women's Hospital
Conditions studied	Obesity, Overweight
GLP-1 drugs	semaglutide, tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07619508 ↗